echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Ivosidenib is safe for the treatment of gliomas and can slow down the growth rate of tumors

    J Clin Oncol: Ivosidenib is safe for the treatment of gliomas and can slow down the growth rate of tumors

    • Last Update: 2021-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Diffuse glioma is a malignant brain tumor, including low-grade glioma (LGG) and glioblastoma.


    The study included 66 patients with advanced glioma, ivosidenib was administered orally every day for a period of 28 days.


     

    The results showed that ivosidenib was well tolerated and no dose-related toxicity was reported.


     

    Among patients with non-enhanced glioma (n = 35), the objective response rate was 2.


     

    The median progression-free survival in the non-enhanced and enhanced glioma cohorts were 13.


    In summary, the results of this study show that in patients with mIDH1 advanced glioma, ivosidenib 500 mg once a day has good safety, prolongs the time of disease control, and reduces the growth rate of non-enhanced tumors.


     

    Original source:

     

    Ingo K Mellinghoff, et al.


    ncbi.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.